Catherine Abrial is an expert in Oncology at Centre Jean Perrin (France). Catherine Abrial has authored 119 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 2 of them ongoing. SLR score: 375 (community average: 125). How the SLR is computed.

LeadR Profile

Catherine Abrial Centre Jean Perrin France
375 ScienceLeadR Reputation 375
Network Map

Oncology

Subspecialties: Public Health - Gynecology - Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2004 - 2026

Source: PubMed

Centre Jean Perrin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 119

Citations

Citations: 2 433 1st author: 14 Last author: 3 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Impact of Implementing the Modified Assessment of the Difficulty of Intravenous Access Scale on First-Attempt Venous Access Success: Study Protocol for the Multicenter Prospective Before-and-After Controlled DIVAPERF Trial.
PMID 42857443 — nurses, therapeutics
Health Sci Rep20260
Study Protocol for Assessment of the Feasibility of an Intraoperative Localization Technique Using Augmented Reality in Breast-Conserving Surgery for Non-Palpable Cancer Lesions: A Feasibility Study.
PMID 42661930 — feasibility studies, breast neoplasms, augmented reality, neoplasms, breast, wounds and injuries
Health Sci Rep20260
Circulating proteins as biomarkers of response to cancer immunotherapy (Review).
PMID 42099246 — cells, lymphocytes, neoplasms, biomarkers, immunotherapy, therapeutics, t-lymphocytes, liquid biopsy
Int J Oncol20260
Patient-reported satisfaction with thermal water-based cosmetic products in breast cancer patients undergoing chemotherapy: a feasibility study.
PMID 41812302 — skin, feasibility studies, breast neoplasms, neoplasms, drug therapy, breast, therapeutics, chemotherapy
Cancer Treat Res Commun20260
Identification of serum proteins associated with response of triple-negative breast cancer to neoadjuvant chemotherapy: preliminary results from the INSTIGO trial.
PMID 41462069 — triple negative breast neoplasms, serum, breast neoplasms, neoplasms, drug therapy, biomarkers, breast, chemotherapy
Clin Proteomics20250

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 5
Phase 2 3

By status:

Completed 4
Active not recruiting 3
Recruiting 1

By type:

Interventional 4
Observational 4

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 2
multicentricup10 2

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Impact of Implementing the Modified A DIVA Scale on Successful Access to a Venous Line on the First Attempt
NCT06062199 — nurses, chronic disease, pain
N/ARecruiting2024
Support and Post therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment
NCT05433077 — quality of life, breast neoplasms, neoplasms, rehabilitation, breast, therapeutics, environment, carcinoma, women
N/AActive not recruiting2022

LeadR Networks

Main global connection map